Pinpoint Therapeutics, Inc., a Philadelphia, PA-based biopharmaceutical company focused on the development of novel autophagy inhibitors to treat cancer, raised $1 million in debt financing.
The companyâ€™s novel compounds target a recently discovered enzyme in the autophagy pathway called PPT1, which is highly expressed across most cancers.
These inhibitors could be applied to a broad range of cancers alone or in combination with other treatments to overcome therapy resistance.
Pinpoint will develop first-in-class autophagy inhibitors into clinical drugs for testing in a range of treatment-refractory cancers.
Pinpoint was launched in 2018 through PCI Ventures, a division of the Penn Center for Innovation (PCI) at the University of Pennsylvania.
Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
Advertise with us to boost your article, content pience, product, event, conference discovery to our readers which includes founders, startup enablers, investors and every key stakeholders from global startup eco-system.